Which statement about Lipoprotein(a) is true?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which statement about Lipoprotein(a) is true?

Lipoprotein(a) adds cardiovascular risk on its own, beyond what traditional lipids explain. Its structure combines an LDL-like particle with an apolipoprotein(a) cap that resembles plasminogen, which gives it both pro-atherogenic and pro-thrombotic properties. This means higher Lp(a) levels are linked to more plaque formation and reduced fibrinolysis, increasing ASCVD risk independently of LDL-C or non-HDL-C levels. Epidemiologic data show that risk rises with higher Lp(a) across diverse populations, and this association persists after adjusting for common risk factors. Because Lp(a) is largely genetically determined and remains relatively constant over life, lifestyle changes have limited effect on its level, and statins typically don’t meaningfully lower it. That’s why recognizing Lp(a) as a separate risk factor helps explain why some patients with well-controlled LDL-C still experience ASCVD events. Measuring Lp(a) is helpful in individuals with premature ASCVD or a strong family history to better gauge overall risk, and there are established thresholds that indicate elevated risk. While therapies that specifically lower Lp(a) exist for some patients, and ongoing antisense approaches show promise, the key point remains: Lp(a) independently contributes to ASCVD risk and should not be ignored in risk assessment.

Lipoprotein(a) adds cardiovascular risk on its own, beyond what traditional lipids explain. Its structure combines an LDL-like particle with an apolipoprotein(a) cap that resembles plasminogen, which gives it both pro-atherogenic and pro-thrombotic properties. This means higher Lp(a) levels are linked to more plaque formation and reduced fibrinolysis, increasing ASCVD risk independently of LDL-C or non-HDL-C levels.

Epidemiologic data show that risk rises with higher Lp(a) across diverse populations, and this association persists after adjusting for common risk factors. Because Lp(a) is largely genetically determined and remains relatively constant over life, lifestyle changes have limited effect on its level, and statins typically don’t meaningfully lower it. That’s why recognizing Lp(a) as a separate risk factor helps explain why some patients with well-controlled LDL-C still experience ASCVD events.

Measuring Lp(a) is helpful in individuals with premature ASCVD or a strong family history to better gauge overall risk, and there are established thresholds that indicate elevated risk. While therapies that specifically lower Lp(a) exist for some patients, and ongoing antisense approaches show promise, the key point remains: Lp(a) independently contributes to ASCVD risk and should not be ignored in risk assessment.

More practice questions